Clinical Trial: Prospective Exploration of Vascular Complications Associated With the Use of Immune Checkpoint Inhibitors

U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT07535944) titled 'Prospective Exploration of Vascular Complications Associated With the Use of Immune Checkpoint Inhibitors' on April 10.

Brief Summary: The development of immune checkpoint inhibitors (ICIs) has revolutionized the management of many oncological diseases, and their use continues to increase. ICIs are monoclonal antibodies that target immune checkpoints such as PD-1 (programmed cell death protein 1, as seen in nivolumab, pembrolizumab, and cemiplimab), PD-L1 (programmed cell death protein 1 ligand, as seen in atezolizumab, avelumab, and durvalumab), CTLA-4 (cytotoxic T-lymphocyte antigen 4, as seen in ipilimumab and tremelimumab), or ...